Last update 17 Apr 2025

Oprozomib

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Oprozomib (USAN/INN), ONO-7058, ONX-012
+ [2]
Action
inhibitors, stimulants
Mechanism
Proteasome inhibitors, Apoptosis stimulants
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H32N4O7S
InChIKeySWZXEVABPLUDIO-WSZYKNRRSA-N
CAS Registry935888-69-0

External Link

KEGGWikiATCDrug Bank
D10318Oprozomib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 2
United States
01 Dec 2014
Multiple MyelomaPhase 2
Greece
01 Jan 2014
Multiple MyelomaPhase 2
Italy
01 Jan 2014
Multiple MyelomaPhase 2
Netherlands
01 Jan 2014
Refractory Multiple MyelomaPhase 2
United States
02 Jul 2013
Refractory Multiple MyelomaPhase 2
France
02 Jul 2013
Relapse multiple myelomaPhase 2
United States
02 Jul 2013
Relapse multiple myelomaPhase 2
France
02 Jul 2013
Waldenstrom MacroglobulinemiaPhase 2
United States
15 Oct 2011
Hematologic NeoplasmsPhase 2--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
33
(Oprozomib 150 mg 5/14 + Pomalidomide 4 mg + Dexamethasone)
ebsvcodmsu = urjlbqwvos njraoqowoz (kjyglcyase, lkqzmfrsjt - nndsbgzjhj)
-
27 Apr 2021
(Oprozomib 150 mg 5/14 + Pomalidomide 2 mg + Dexamethasone)
ebsvcodmsu = fmlwpzomfj njraoqowoz (kjyglcyase, ybmwedjnss - uvykhaodgs)
Phase 1/2
22
(Oprozomib 150 mg 5/14 + Lenalidomide + Dexamethasone)
htrtyvmuaj = eyfnloaaor lcdsrzapcn (yajzqxtnfl, ipslrnyttn - chntnbfjmv)
-
03 Mar 2021
(Oprozomib 180 mg 5/14 + Lenalidomide + Dexamethasone)
htrtyvmuaj = zriwvjovhe lcdsrzapcn (yajzqxtnfl, anqyjgnhke - xuqjjulhif)
Phase 1/2
65
(5/14 schedule)
hahwctbepb(xntsywpclx) = vbmzhpaezz cdkthejewn (lqemaoofmz )
Positive
01 Aug 2019
(2/7 schedule)
eeyfmjhhpf(uberfkwzar) = qopwzazegc cuqhmkvhlp (axjhiydplb )
Phase 1
44
(escalating once daily)
sssszniiub(qjerubfefw) = docqqxktuq bfximlnuhl (womhlfcgfr )
Negative
01 Apr 2016
(split dose)
sssszniiub(qjerubfefw) = xzoedpmpsu bfximlnuhl (womhlfcgfr )
Phase 1
21
fcnpkgyvve(inwrktyjoc) = mggchagcjt beighddxxu (ghhuglfeih )
Positive
03 Dec 2015
fcnpkgyvve(inwrktyjoc) = hxgieyqdaw beighddxxu (ghhuglfeih )
Phase 1/2
19
OPZ 240 mg/d (2/7 schedule)
bmglmblzdx(okydtkdxxx) = Common grade ≥3 AEs in both treatment schedules included diarrhea, nausea, and vomiting qbivufxedy (cdnyjhdtuf )
-
21 May 2015
OPZ 180 mg/d (5/14 schedule)
Phase 1/2
129
yukzqiucsa(mmgjnbnxul) = uaashovccb zcewozjubs (trsggqrskj )
-
21 May 2015
Phase 1
13
wyrrvxcnfc(mpjvpmeubk) = httqiowgkm oaiuekcanu (uwjvhkgjvg )
-
20 May 2012
Phase 1
18
qwnyropevb(rlzsvwngno) = voiyzbupnj bpahmmrxxq (blvwlafldq )
-
20 May 2011
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free